Experienced clinical development leader with 16 years of expertise in oncology and immunology, driving early to late-phase trials for novel targeted therapies and biologics. Proven success in leading IND submissions, Phase 1–3 trials, global regulatory strategy, and medical monitoring. Strong cross-functional collaborator with experience spanning biotech and large pharma. Demonstrated leadership in protocol development, data analysis, FDA interactions, and scientific communications. Recognized for advancing precision oncology programs and forging key opinion leader relationships to support global trial execution.